- Report
- November 2024
- 50 Pages
Global
From €2618EUR$2,650USD£2,179GBP
- Report
- November 2024
- 50 Pages
Global
From €2618EUR$2,650USD£2,179GBP
- Report
- November 2024
- 50 Pages
Global
From €2618EUR$2,650USD£2,179GBP
- Report
- November 2024
- 50 Pages
Global
From €2618EUR$2,650USD£2,179GBP
- Report
- September 2024
- 74 Pages
China
From €1779EUR$1,800USD£1,480GBP
- Report
- September 2024
- 103 Pages
China
From €1779EUR$1,800USD£1,480GBP
- Report
- July 2024
- 280 Pages
Global
From €2623EUR$2,655USD£2,183GBP
- Report
- September 2022
- 251 Pages
Global
From €3527EUR$3,570USD£2,936GBP
The Skin Cancer Drugs market is a segment of the pharmaceutical industry that focuses on the development and sale of drugs used to treat skin cancer. These drugs are used to treat a variety of skin cancer types, including melanoma, basal cell carcinoma, and squamous cell carcinoma. The drugs are typically administered orally, intravenously, or topically.
The market is highly competitive, with many companies offering a variety of treatments. Some of the major players in the market include Bristol-Myers Squibb, Merck & Co., Novartis, Pfizer, and Roche. These companies are constantly researching and developing new treatments to improve the efficacy of existing treatments and to develop new treatments for skin cancer.
In addition to the major players, there are also many smaller companies that are developing treatments for skin cancer. These companies are often focused on developing treatments for rarer forms of skin cancer, such as Merkel cell carcinoma. Examples of these companies include Aduro Biotech, Arcutis Biotherapeutics, and OncoSec Medical. Show Less Read more